Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Financial Report: Merck | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

Financial Report: Merck

Pharma sales up 2%, hurt by Remicade settlement

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Merck
 
2Q Revenues: $12.3 billion (+1%)

2Q Earnings: $1.8 billion (-11%)

YTD Revenues: $24.0 billion (+1%)

YTD Earnings: $3.6 billion (+15%)

Comments: Pharmaceutical sales were up 2% to $10.6 billion in the quarter. Singulair sales were $1.4 billion (+6%). Januvia sales were up 36% to $1.1 billion. Zetia sales were up 7% to $632 million. Janumet sales were 28% to $411 million. Gardasil sales were up 17% to $324 million. Remicade sales were down 38%, impacted by territories transferred to Johnson & Johnson through a settlement agreement. Cozaar/Hyzaar sales were down 17% to $337 million. Earnings were down partly as a result of ongoing restructuring costs.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters